http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김세란,이진원,임소연,정유선,최해윤,김종대,Kim, Se-Ran,Lee, Jin-Won,Lim, So-Yeon,Jung, Yu-Sun,Choi, Hae-Yun,Kim, Jong-Dae 대한한방내과학회 2012 大韓韓方內科學會誌 Vol.33 No.2
Objectives : The object of this study was to obtain acute toxicity information (single oral dose toxicity) of Armeniacae Semen (AS), a medicinal herb used for treating constipation and various respiratory diseases, in rats. Methods : In order to observe the $LD_{50}$ (50% lethal dose), approximate lethal dosage (ALD) and target organs, AS aqueous extracts were orally administered once to female and male Sprague Dawley rats at dose levels of 2,000, 1,000, 500 and 0 (control) mg/kg (body weight). The mortality, changes in the body weight, clinical signs and gross observation were monitored for 14 days after single oral treatment of AS extracts, and the organ weights and histopathological findings of principle organs were observed after sacrifice. Results : After single oral treatment of AS 2,000 and 1,000 mg/kg, all (5/5; 100%) female and male rats died within 30 minutes after treatment, while no mortalities were observed in the female and male rats treated with 500 mg/kg of AS extract. Therefore, $LD_{50}$ in female and male rats was calculated as 741.95 mg/kg. Seizure, loss of locomotion, salivation, increases of respiration and heart-beat were observed after AS extract treatment, which were observed in all rats including the lowest dosage group, 500 mg/kg in the present study. In addition, lung congestion was visible in all mortal rats with AS 2,000 and 1,000 mg/kg, respectively. Conclusions : The results obtained in this study suggest that AS extract ranges in Class III, because the $LD_{50}$ and ALD in both female and male rats were calculated as 741.95 mg/kg and 500~1,000 mg/kg, respectively. However, AS extract should be carefully treated at clinical applications, because salivation, increase of respiration and heart-beat were also observed in the lowest dosage group, 500 mg/kg in the present study.
INTEGRATED CAD/CAM FOR NANOSCALE 3D PRINTING USING AFN PRINTING AND FIB
Hae-Sung Yoon(윤해성),Ki-Hwan Jang(장기환),Eun-Seob Kim(김은섭),Hyun-Taek Lee(이현택),Hyunseo Park(박현서),Dae-Wook Kim(김대욱),Chung-Soo Kim(김충수),Gil-Yong Lee(이길용),Kunwoo Lee(이건우),Sung-Hoon Ahn(안성훈) (사)한국CDE학회 2015 한국 CAD/CAM 학회 학술발표회 논문집 Vol.2015 No.동계
Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia
Dae Kyung Sohn,Seung Yong Jeong,Hyo Seong Choi,Seok Byung Lim,Jin Myeong Huh,Dae Hyun Kim,김대용,Young Hoon Kim,Hee Jin Chang,Kyung Hae Jung,Joong Bae Ahn,Hyun Kyung Kim,Jae Gahb Park 대한암학회 2005 Cancer Research and Treatment Vol.37 No.1
Purpose: This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia. Materials and Methods: A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia , Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer (Eiken Chemical Co. Tokyo, Japan). Results: Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detec- ting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively. Conclusion: The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A.